Maywufa Company Ltd. (1731.TW)
TWD 22.25
(0.23%)
TWD 22.25
(0.23%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 239.81 Million TWD | 0.11% |
| 2022 | 239.54 Million TWD | -3.2% |
| 2021 | 268.5 Million TWD | 15.96% |
| 2020 | 268.02 Million TWD | 18.92% |
| 2019 | 217.88 Million TWD | 22.48% |
| 2018 | 185.79 Million TWD | -10.0% |
| 2017 | 193.15 Million TWD | 13.61% |
| 2016 | 183.69 Million TWD | 7.3% |
| 2015 | 133.55 Million TWD | -14.05% |
| 2014 | 182.28 Million TWD | 46.37% |
| 2013 | 105.44 Million TWD | 3.92% |
| 2012 | 80.39 Million TWD | 99.5% |
| 2011 | 117.84 Million TWD | 28.82% |
| 2010 | 39.74 Million TWD | 1045.73% |
| 2009 | 117.32 Million TWD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 57.04 Million TWD | -33.05% |
| 2024 Q1 | 79.64 Million TWD | 87.55% |
| 2023 Q2 | 62.2 Million TWD | -17.28% |
| 2023 Q1 | 75.19 Million TWD | 104.97% |
| 2023 Q4 | 45.43 Million TWD | -20.27% |
| 2023 Q3 | 56.98 Million TWD | -8.38% |
| 2023 FY | - TWD | 0.11% |
| 2022 Q1 | 72.51 Million TWD | 106.21% |
| 2022 Q3 | 63.28 Million TWD | -5.59% |
| 2022 FY | - TWD | -3.2% |
| 2022 Q4 | 36.68 Million TWD | -42.03% |
| 2022 Q2 | 67.03 Million TWD | -7.56% |
| 2021 FY | - TWD | 15.96% |
| 2021 Q1 | 68.58 Million TWD | 108.74% |
| 2021 Q2 | 76.02 Million TWD | 10.85% |
| 2021 Q3 | 67.69 Million TWD | -10.95% |
| 2021 Q4 | 35.16 Million TWD | -48.06% |
| 2020 FY | - TWD | 18.92% |
| 2020 Q2 | 51.61 Million TWD | -10.95% |
| 2020 Q1 | 57.96 Million TWD | 204.03% |
| 2020 Q3 | 70.96 Million TWD | 37.49% |
| 2020 Q4 | 32.85 Million TWD | -53.7% |
| 2019 Q1 | 66.32 Million TWD | 726.96% |
| 2019 Q3 | 47.3 Million TWD | 1.17% |
| 2019 Q4 | 19.06 Million TWD | -59.7% |
| 2019 FY | - TWD | 22.48% |
| 2019 Q2 | 46.76 Million TWD | -29.49% |
| 2018 FY | - TWD | -10.0% |
| 2018 Q2 | 42.48 Million TWD | -6.36% |
| 2018 Q1 | 45.36 Million TWD | 56.75% |
| 2018 Q4 | 8.02 Million TWD | -84.17% |
| 2018 Q3 | 50.65 Million TWD | 19.24% |
| 2017 Q2 | 43.52 Million TWD | 14.51% |
| 2017 Q3 | 52.32 Million TWD | 20.24% |
| 2017 FY | - TWD | 13.61% |
| 2017 Q1 | 38 Million TWD | -10.95% |
| 2017 Q4 | 28.94 Million TWD | -44.69% |
| 2016 Q3 | 47.78 Million TWD | 87.51% |
| 2016 FY | - TWD | 7.3% |
| 2016 Q4 | 42.68 Million TWD | -10.69% |
| 2016 Q2 | 25.48 Million TWD | -6.79% |
| 2016 Q1 | 27.34 Million TWD | -25.69% |
| 2015 Q2 | 23.63 Million TWD | -49.43% |
| 2015 Q1 | 46.73 Million TWD | 60.28% |
| 2015 FY | - TWD | -14.05% |
| 2015 Q4 | 36.79 Million TWD | 39.41% |
| 2015 Q3 | 26.39 Million TWD | 11.69% |
| 2014 Q3 | 68.74 Million TWD | 181.44% |
| 2014 Q2 | 24.42 Million TWD | -26.11% |
| 2014 FY | - TWD | 46.37% |
| 2014 Q1 | 33.05 Million TWD | -4.39% |
| 2014 Q4 | 29.15 Million TWD | -57.59% |
| 2013 Q4 | 34.57 Million TWD | 33.45% |
| 2013 Q2 | 15.5 Million TWD | -48.6% |
| 2013 Q3 | 25.9 Million TWD | 67.09% |
| 2013 FY | - TWD | 3.92% |
| 2013 Q1 | 30.16 Million TWD | -20.01% |
| 2012 Q4 | 37.71 Million TWD | 22.12% |
| 2012 Q1 | 28.62 Million TWD | 34.0% |
| 2012 Q2 | 18.7 Million TWD | -34.66% |
| 2012 Q3 | 30.88 Million TWD | 65.14% |
| 2012 FY | - TWD | 99.5% |
| 2011 FY | - TWD | 28.82% |
| 2011 Q3 | 6.59 Million TWD | 266.58% |
| 2011 Q2 | -3.95 Million TWD | -114.55% |
| 2011 Q1 | 27.2 Million TWD | 777.01% |
| 2011 Q4 | 21.36 Million TWD | 223.9% |
| 2010 Q3 | 6.73 Million TWD | -50.47% |
| 2010 Q2 | 13.6 Million TWD | -41.95% |
| 2010 FY | - TWD | 1045.73% |
| 2010 Q1 | 23.43 Million TWD | 0.0% |
| 2010 Q4 | -4.01 Million TWD | -159.66% |
| 2009 FY | - TWD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Grape King Bio Ltd | 2.88 Billion TWD | 91.687% |
| Standard Chem & Pharm CO., LTD. | 1.57 Billion TWD | 84.812% |
| ScinoPharm Taiwan, Ltd. | 819.15 Million TWD | 70.724% |
| Lotus Pharmaceutical Co., Ltd. | 6.87 Billion TWD | 96.51% |
| LIWANLI Innovation Co., Ltd. | 6.81 Million TWD | -3421.498% |
| YungShin Global Holding Corporation | 1.35 Billion TWD | 82.332% |
| PhytoHealth Corporation | -20.69 Million TWD | 1258.634% |
| SCI Pharmtech, Inc. | 529.61 Million TWD | 54.719% |
| Formosa Laboratories, Inc. | 1.16 Billion TWD | 79.385% |
| PharmaEssentia Corporation | -671.48 Million TWD | 135.714% |
| Bora Pharmaceuticals Co., LTD. | 5.73 Billion TWD | 95.818% |